129 related articles for article (PubMed ID: 26138535)
1. Living with CML: is death no longer the end (point)?
White DL; Hughes TP
Blood; 2015 Jul; 126(1):2-4. PubMed ID: 26138535
[No Abstract] [Full Text] [Related]
2. Chronic myelogenous leukemia: an overview.
Tennant L
Clin J Oncol Nurs; 2001; 5(5):218-9. PubMed ID: 11899767
[TBL] [Abstract][Full Text] [Related]
3. Chronic myelogenous leukemia: biology and therapy.
Gale RP; Grosveld G; Canaani E; Goldman JM
Leukemia; 1993 Apr; 7(4):653-8. PubMed ID: 8464245
[TBL] [Abstract][Full Text] [Related]
4. Chronic myelogenous leukemia--past, present, and future.
Kantarjian HM; Talpaz M; Gutterman JU
Hematol Pathol; 1988; 2(2):91-120. PubMed ID: 3058675
[No Abstract] [Full Text] [Related]
5. Chronic myeloid leukemia in 2007.
Sessions J
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S4-9. PubMed ID: 18056931
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
[TBL] [Abstract][Full Text] [Related]
7. What's blasting off in CML?
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):71-2. PubMed ID: 17824574
[No Abstract] [Full Text] [Related]
8. Epidemiology of chronic myeloid leukaemia (CML).
Rohrbacher M; Hasford J
Best Pract Res Clin Haematol; 2009 Sep; 22(3):295-302. PubMed ID: 19959081
[TBL] [Abstract][Full Text] [Related]
9. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
[TBL] [Abstract][Full Text] [Related]
10. Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
Luo Z; Gao M; Huang N; Wang X; Yang Z; Yang H; Huang Z; Feng W
J Exp Clin Cancer Res; 2019 May; 38(1):224. PubMed ID: 31138265
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
Sengupta A; Banerjee D; Chandra S; Banerjee S
J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
[TBL] [Abstract][Full Text] [Related]
12. The role of comorbidities in chronic myeloid leukemia.
Breccia M; Alimena G
Leuk Res; 2013 Jul; 37(7):729-30. PubMed ID: 23628553
[No Abstract] [Full Text] [Related]
13. Biologically based risk estimation for radiation-induced CML. Inferences from BCR and ABL geometric distributions.
Radivoyevitch T; Kozubek S; Sachs RK
Radiat Environ Biophys; 2001 Mar; 40(1):1-9. PubMed ID: 11357705
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia: Is it dusk or dawn?
Mauro MJ
Best Pract Res Clin Haematol; 2016 Sep; 29(3):249-251. PubMed ID: 27839565
[No Abstract] [Full Text] [Related]
15. Chronic myelogenous leukemia.
Osarogiagbon UR; McGlave PB
Curr Opin Hematol; 1999 Jul; 6(4):241-6. PubMed ID: 10400373
[TBL] [Abstract][Full Text] [Related]
16. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
17. Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia.
Corsetti MT; Lerma E; Dejana A; Basta P; Ferrara R; Benvenuto F; Vassallo F; Abate M; Piaggio G; Parodi C; Sessarego M; Li Pira G; Manca F; Carella AM
Leukemia; 1999 Jul; 13(7):999-1008. PubMed ID: 10400414
[TBL] [Abstract][Full Text] [Related]
18. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
Baccarani M; Abruzzese E; Accurso V; Albano F; Annunziata M; Barulli S; Beltrami G; Bergamaschi M; Binotto G; Bocchia M; Caocci G; Capodanno I; Cavazzini F; Cedrone M; Cerrano M; Crugnola M; D'Adda M; Elena C; Fava C; Fazi P; Fozza C; Galimberti S; Giai V; Gozzini A; Gugliotta G; Iurlo A; La Barba G; Levato L; Lucchesi A; Luciano L; Lunghi F; Lunghi M; Malagola M; Marasca R; Martino B; Melpignano A; Miggiano MC; Montefusco E; Musolino C; Palmieri F; Pregno P; Rapezzi D; Rege-Cambrin G; Rupoli S; Salvucci M; Sancetta R; Sica S; Spadano R; Stagno F; Tiribelli M; Tomassetti S; Trabacchi E; Bonifacio M; Breccia M; Castagnetti F; Pane F; Russo D; Saglio G; Soverini S; Vigneri P; Rosti G
Blood Adv; 2019 Dec; 3(24):4280-4290. PubMed ID: 31869412
[TBL] [Abstract][Full Text] [Related]
19. Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up.
Hochhaus A; Dreyling M;
Ann Oncol; 2008 May; 19 Suppl 2():ii63-4. PubMed ID: 18456772
[No Abstract] [Full Text] [Related]
20. How I manage Chronic Myeloid Leukemia in 2015.
Kaur V; Adballah AO; Ziang Z
J Ark Med Soc; 2016 Aug; 113(2):43-45. PubMed ID: 30047632
[No Abstract] [Full Text] [Related]
[Next] [New Search]
